Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$1.88M$1.88Mno prior Q1 2021 on file Net Income-$34.07M-$34.07Mno prior Q1 2021 on file EPS Diluted-$0.83-$0.83no prior Q1 2021 on file Operating Income-$34,235,000— The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end